Literature DB >> 22461680

Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis.

Charles R Sims1, Siraya Jaijakul, John Mohr, Jose Rodriguez, Malcolm Finkelman, Luis Ostrosky-Zeichner.   

Abstract

The correlation of β-glucan (BG) levels with clinical outcomes in invasive candidiasis (IC) remains unknown. Patients with proven IC were followed prospectively from diagnosis to outcome with twice-weekly serum BG sampling. Correlation of BG with clinical outcome was assessed in each patient. BG levels tend to decrease in successfully treated patients and increase in treatment failures. BG levels may be useful as surrogates for outcome evaluation of IC.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22461680      PMCID： PMC3372136          DOI： 10.1128/JCM.00773-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Potential use of (1,3)-beta-D-glucan as target of diagnosis and treatment of keratomycosis.

Authors:  Yuichi Kaji; Takahiro Hiraoka; Tetsuro Oshika
Journal:  Cornea       Date:  2004-11       Impact factor: 2.651

Review 2.  Fungal infections in iatrogenically compromised hosts.

Authors:  J H Rex; T J Walsh; E J Anaissie
Journal:  Adv Intern Med       Date:  1998

3.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis.

Authors:  Drosos E Karageorgopoulos; Evridiki K Vouloumanou; Fotinie Ntziora; Argyris Michalopoulos; Petros I Rafailidis; Matthew E Falagas
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

4.  Beta -1,3 glucan as a test for central venous catheter biofilm infection.

Authors:  Jeniel Nett; Leslie Lincoln; Karen Marchillo; David Andes
Journal:  J Infect Dis       Date:  2007-04-17       Impact factor: 5.226

5.  Nosocomial candidemia: risk factors and attributable mortality.

Authors:  R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

6.  Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis.

Authors:  N Kondori; L Edebo; I Mattsby-Baltzer
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

7.  Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Zekaver Odabasi; Gloria Mattiuzzi; Elihu Estey; Hagop Kantarjian; Fumihiro Saeki; Richard J Ridge; Paul A Ketchum; Malcolm A Finkelman; John H Rex; Luis Ostrosky-Zeichner
Journal:  Clin Infect Dis       Date:  2004-06-28       Impact factor: 9.079

8.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
  9 in total
  16 in total

1.  Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Authors:  P Pini; C Bettua; C F Orsi; C Venturelli; F Forghieri; S Bigliardi; L Faglioni; F Luppi; L Serio; M Codeluppi; M Luppi; C Mussini; M Girardis; Elisabetta Blasi
Journal:  Infection       Date:  2015-10-16       Impact factor: 3.553

2.  Monitoring Anti-Pythium insidiosum IgG Antibodies and (1→3)-β-d-Glucan in Vascular Pythiosis.

Authors:  Navaporn Worasilchai; Nitipong Permpalung; Pakawat Chongsathidkiet; Asada Leelahavanichkul; Alberto Leonel Mendoza; Tanapat Palaga; Rangsima Reantragoon; Malcolm Finkelman; Pranee Sutcharitchan; Ariya Chindamporn
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

3.  Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!

Authors:  Gennaro De Pascale; Brunella Posteraro; Salvatore Lucio Cutuli; Anselmo Caricato; Domenico Lepore; Mario Tumbarello; Mariano Alberto Pennisi; Maurizio Sanguinetti; Massimo Antonelli
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

4.  Reply to "Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!".

Authors:  Siraya Jaijakul; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2013-05       Impact factor: 5.948

5.  β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.

Authors:  Estrella Martín-Mazuelos; Ana Loza; Carmen Castro; Desirée Macías; Ismail Zakariya; Pedro Saavedra; Sergio Ruiz-Santana; Elena Marín; Cristóbal León
Journal:  Intensive Care Med       Date:  2015-07-02       Impact factor: 17.440

6.  Comparison of Serum Galactomannan and 1,3-Beta-D-Glucan Determination for Early Detection of Invasive Pulmonary Aspergillosis in Critically Ill Patients with Hematological Malignancies and Septic Shock.

Authors:  Tobias Lahmer; Sebastian Rasch; Christopher Schnappauf; Analena Beitz; Roland M Schmid; Wolfgang Huber
Journal:  Mycopathologia       Date:  2016-05-03       Impact factor: 2.574

7.  Prognostic Potential of the Panfungal Marker (1 → 3)-β-D-Glucan in Invasive Mycoses Patients.

Authors:  P Pini; C Venturelli; M Girardis; F Forghieri; E Blasi
Journal:  Mycopathologia       Date:  2018-07-02       Impact factor: 2.574

Review 8.  Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients.

Authors:  Jean-François Timsit; Sarah Chemam; Sébastien Bailly
Journal:  F1000Prime Rep       Date:  2015-02-03

9.  β-d-Glucan and Aspergillus Galactomannan assays in the diagnosis of invasive fungal infections.

Authors:  Mahadevan Kumar; M Mugunthan
Journal:  Med J Armed Forces India       Date:  2017-11-28

10.  EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.

Authors:  Jean-François Timsit; Elie Azoulay; Muriel Cornet; Jean-Pierre Gangneux; Vincent Jullien; Aurélien Vésin; Edith Schir; Michel Wolff
Journal:  Trials       Date:  2013-11-21       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.